WISE S.p.A., a Milan-based medical device company developing advanced implantable electrodes, has closed an oversubscribed €30 million Series D financing round to accelerate its neurotechnology pipeline. The round brings ENEA Tech and Biomedical into the company’s shareholder base as a strategic investor focused on biomedical innovation and technology transfer in Italy. The financing strengthens WISE’s ability to move its lead products toward broader clinical and commercial use across neuromonitoring, neuromodulation, and brain-computer interface applications.
Funding Strategy
The final closing expands a Series D process that began with an initial closing in June 2024 and now gives WISE additional resources for product development, regulatory work, and market expansion. Earlier participants included a venture debt facility from the European Investment Bank backed by InvestEU, new investor Wallaby S.p.A., and existing financial partners New Frontier, Eureka Venture SGR, and Indaco Ventures SGR. By adding ENEA Tech and Biomedical, WISE is also deepening its connection to Italy’s biomedical innovation ecosystem as it prepares for the next stage of growth.
Advancing Heron Lead
A central focus of the new capital will be the Heron lead, WISE’s flagship product for spinal cord stimulation and a core part of its strategy in chronic pain treatment. The device is designed to deliver targeted, directional stimulation through a minimally invasive percutaneous implant technique, combining the precision typically associated with surgical paddle leads with the lighter procedural profile of cylindrical leads. WISE says this approach can support improved energy efficiency, stronger anatomical coverage, better neural signal sensing, and reduced lead migration.
Technology Platform
WISE’s product portfolio is built on its proprietary Supersonic Technology, which enables stretchable electronic circuits to be integrated into ultra-thin elastomeric foils. This design gives the company’s electrodes a softer and more conformable structure than conventional rigid devices, which is important for contact with delicate neural tissue. The same technology underpins WISE’s broader ambitions in next-generation neural interfaces, where precision, safety, and long-term tissue compatibility remain central technical challenges.
Commercial Progress
Beyond the Heron lead, the funding will also support the continued commercial expansion of the WISE Cortical Strip, known as WCS. The product is used for intraoperative neurophysiological monitoring during brain tumor and epilepsy surgeries and is described by the company as the first soft, stretchable electrode for this application. WCS has received CE marking under the European Medical Device Regulation, holds FDA clearance, and is commercially available in Europe, the United States, and Australia.
Governance and Market Outlook
The financing also comes with governance changes, including the appointment of Laura Iris Ferro as chairperson and the addition of Giuseppe Corvino to the board of directors. Ferro brings extensive life sciences experience, including her role as founder of Gentium, the Nasdaq-listed company acquired by Jazz Pharmaceuticals in a transaction valued at about $1 billion. Her appointment adds operational and investment expertise as WISE seeks to scale from research-led development into wider clinical adoption.
WISE’s oversubscribed Series D marks an important step for a company working at the intersection of materials science, neuroscience, and medical device commercialization. With €30 million secured, the company plans to advance the Heron lead through regulatory certification and first-in-human clinical work while expanding its electrode portfolio in international markets. The round positions WISE to pursue a larger role in neurostimulation and neuromonitoring as demand grows for less invasive and more precise technologies addressing chronic pain and neurological conditions.